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Abstract: Pityriasis lichenoides comprises a clinicopathological spectrum of cutaneous
inflammatory disorders, with the two most common variants, pityriasis lichenoides et
varioliformis acuta (PLEVA) and pityriasis lichenoides chronica. The aim of the study is
to describe 13 cases of a unique PLEVA variant characterized with a conspicuous
CD30+ component and thus mimicking lymphomatoid papulosis (LyP), a condition
currently classified with a spectrum of CD30+ lymphoproliferative disorders. The cohort
included 10 female and 3 male patients whose age at diagnosis ranged from 7 to 89
years (mean 41 years; median 39 years). The clinical manifestation was that of
PLEVA, with small erythematous macules quickly evolving into necrotic papules. There
was no waxing and waning course on follow-up in any of the cases.
Histopathologically, typical features of PLEVA were present but an unusual finding was
occurrence of a considerable number of CD30+ small lymphocytes as detected
immunohistochemically. Over half of the cases also displayed a high number of CD8-
positive cells and showed co-expression of CD8 and CD30 in the intraepidermal and
dermal component of the infiltrate. Of the 11 cases of PLEVA studied for TCR gene
rearrangement, 6 evidenced a monoclonal T-cell population and 5 were polyclonal.
Parvovirus B19 (PVB19) DNA was identified in 4 of 10 cases investigated and positive
serology for PVB19 in two patients, altogether suggesting that PVB19 is
pathogenetically linked to PLEVA at least in a subset of cases. The presence of CD30-
positive lymphocytes and CD8-positive lymphocytes would be consistent with an
inflammatory antiviral response, since CD30-positive, even atypically appearing
lymphoid cells have been identified in some viral skin diseases. The main significance
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of the PLEVA variant is however its potential confusion with LyP or some cytotoxic
lymphomas. Admittedly, the CD30+ PLEVA variant described herein and LyP show a
great overlap if one takes into account all known variations of the two conditions
recognized in recent years, thus suggesting that LyP and PLEVA may be much more
biologically closely related entities than currently thought or even can occur on a
clinicopathological spectrum.
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cost of color production, please not that we have now added 2 composites 
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We have also added one reference (Ref. 8) – this paper has just been published 
and we feel this reference would be relevant as it further supports some of our 
ideas in  the Discussion. 
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Enclosed please also find our replies to the referees’ comments. 
We thank you and both reviewers for your time and consideration. 
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Werner Kempf, MD 
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Reviewer #1:  
This is a careful study of what appears to be a subgroup of pityriasis 
lichenoides, with CD30 positive cells and co-expression of CD8.  The authors 
make a convincing case that this is a different disorder from lymphomatoid 
papulosis, but also suggest that these may all be closely related diseases.  The 
association with parvovirus B19 is also interesting, supporting the previous 
study by Tomasini and the long-held suspicions by clinicians that PLEVA may 
be virally-induced.  Further, this group of disorders could represent a family of 
T-cell dyscrasias induced by parvovirus or other infectious or non-infectious 
agents.   
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We thank the reviewer for his/her time and high evaluation of our manuscript. 
With respect of the hypothesis that the entities we report on might represent a 
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CD30+ cells: a variant mimicking lymphomatoid papulosis and other 
cutaneous lymphomas. A clinicopathological, immunohistochemical and 
molecular biological study of 13 cases  
 is a description of 13 cases of PLEVA and PLC with an unusual component of 
CD30+ cells mimicking lymphomatoid papulosis using H and E stains, 
immunochemistry and polymerase chain reaction.  The authors study these 
cases for Parvovirus 19 and detect its presence in 40% of cases, confirming a 
single prior study.  The authors contrast the clinicopathologic features of these 
entities. 
  
 This paper is well written and precise with excellent photographic 
representation and extensive up to date refernces.  It describes a dilemma that 
dermatopathologists face and offers sound criteria.  Although much of this 
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occur in the laboratory setting rather than the neat demarcations described in 
textbooks. 
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We thank the referee for his/her time and high evaluation of our manuscript.  
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Abstract 
Pityriasis lichenoides comprises a clinicopathological spectrum of cutaneous inflammatory 
disorders, with the two most common variants, pityriasis lichenoides et varioliformis acuta 
(PLEVA) and pityriasis lichenoides chronica. The aim of the study is to describe 13 cases of a 
unique PLEVA variant characterized with a conspicuous CD30+ component and thus 
mimicking lymphomatoid papulosis (LyP), a condition currently classified with a spectrum of 
CD30+ lymphoproliferative disorders. The cohort included 10 female and 3 male patients 
whose age at diagnosis ranged from 7 to 89 years (mean 41 years; median 39 years). The 
clinical manifestation was that of PLEVA, with small erythematous macules quickly evolving 
into necrotic papules. There was no waxing and waning course on follow-up in any of the 
cases. Histopathologically, typical features of PLEVA were present but an unusual finding 
was occurrence of a considerable number of CD30+ small lymphocytes as detected 
immunohistochemically. Over half of the cases also displayed a high number of CD8-positive 
cells and showed co-expression of CD8 and CD30 in the intraepidermal and dermal 
component of the infiltrate. Of the 11 cases of PLEVA studied for TCR gene rearrangement, 6 
evidenced a monoclonal T-cell population and 5 were polyclonal. Parvovirus B19 (PVB19) 
DNA was identified in 4 of 10 cases investigated and positive serology for PVB19 in two 
patients, altogether suggesting that PVB19 is pathogenetically linked to PLEVA at least in a 
subset of cases. The presence of CD30-positive lymphocytes and CD8-positive lymphocytes 
would be consistent with an inflammatory antiviral response, since CD30-positive, even 
atypically appearing lymphoid cells have been identified in some viral skin diseases. The 
main significance of the PLEVA variant is however its potential confusion with LyP or some 
cytotoxic lymphomas. Admittedly, the CD30+ PLEVA variant described herein and LyP 
show a great overlap if one takes into account all known variations of the two conditions 
recognized in recent years, thus suggesting that LyP and PLEVA may be much more 
biologically closely related entities than currently thought or even can occur on a 
clinicopathological spectrum. 
 
Key words cutaneous lymphoma, CD30, lymphomatoid papulosis, pityriasis lichenoides, 
Parvovirus B19 
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 3 
Introduction 
Pityriasis lichenoides comprises a clinicopathological spectrum of cutaneous inflammatory 
disorders, of which the two most common variants, pityriasis lichenoides et varioliformis 
acuta (PLEVA) or Mucha–Habermann disease and pityriasis lichenoides chronica are usually 
considered to represent the polar ends, with well-documented intermediate or overlapping 
forms, including concurrent and sequential occurrence of PLEVA and pityriasis lichenoides 
chronica in the same patient. (11), (41), (52) Whereas PLEVA is clinically characterized by 
erythematous papules that rapidly become vesicular and hemorrhagic and finally necrotic and 
ulcerative, pityriasis lichenoides chronica manifests a more monomorphous eruption of 
lichenoid brownish-red, mica-like scaling papules. Compared with adults, childhood pityriasis 
lichenoides has been shown to often run a long-standing and occasionally unremitting course, 
with greater distribution of the lesions, more dyspigmentation, seasonal variation and a poorer 
response to conventional treatment modalities. (23),  (28), (58), (71) A less common but 
apparently distinct variation is febrile ulceronecrotic Mucha-Habermann disease characterized 
by a rapid progression of necrotic papules to large coalescent ulcers with necrotic crusts, 
pustules or hemorrhagic bullae variably accompanied by systemic manifestations (high fever, 
abdominal pain, diarrhea, central nervous system symptoms) and laboratory changes 
(leukocytosis, increased levels of C-protein, anemia etc). Involvement of oral and genital 
mucosa may be encountered and a few fatal cases of febrile ulceronecrotic PLEVA have been 
documented. (17), (18), (25), (56), (63), (67), (68) 
 
Similar to the clinical overlap there is also overlap in the histopathological presentation of the 
above mentioned disease variants. The common features include parakeratosis, spongiosis 
with occasional spongiotic vesicles, mild to moderate acanthosis, vacuolar alteration at the 
dermoepidermal junction, necrotic keratinocytes, lymphocytic perivascular inflammatory 
infiltrate which is often wedge-shaped and obscures the dermoepidermal junction, with 
variable extension into the deeper reticular dermis, and erythrocyte extravasation. 
Angiocentric infiltrates and vasculitic changes can also be encountered on occasion. It is the 
degree of keratinocyte necrosis, erythrocyte extravasation, density of the infiltrate, 
involvement of the deep dermal vascular plexus and presence/severity of vasculitis that vary 
in the clinical forms of pityriasis lichenoides. (7), (35), (48), (57) 
 
Immunohistochemically, the lymphocytic population in PLEVA is mostly represented by 
cytotoxic T cells with the predominance of a memory T-cell subpopulation (CD45RO+, 
CD2+, CD3+, CD8+, TIA-1+, Granzym B–). (29), (36), (65), (75) Subtle variation of the 
immunophenotype of the cells between the intraepidermal and intradermal components can be 
observed. Also, a slight variation in the immunoprofile between individual cases has been 
reported, as has differences in immunoprofile from different lesions from the same patient. A 
handful of cases of PLEVA have been reported in which scattered lymphoid cells expressed 
CD30, (34), (53). Some authors (59) however suggested that these might have in fact 
represented lymphomatoid papulosis (LyP), a condition currently classified in the spectrum of 
the primary cutaneous CD30+lymphoproliferative disorders. (20), (1), (12), (39), (55), (77) 
 
In recent years, we have encountered several unusual cases of PLEVA with a conspicuous 
CD30 +component that warranted, at least from histopathological prospective, a differential 
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 4 
diagnostic consideration of LyP. However, in contrast to LyP, which is characterized by a 
chronic, recurrent, self-healing papular eruption with a typical a waxing and waning course, 
these clinical features were not observed in any of the CD30+ PLEVA cases. The aim of the 
study is to describe 13 cases of this unique PLEVA variant, including molecular biological 
investigations for T-cell clonality and parvovirus B19 (PVB19), and to emphasize its 
differentiation from LyP and other cutaneous lymphomas. The rationale for studying PVB19 
was the conclusions of a recent study on PLEVA in which the authors suggested a causal role 
of the virus in this condition. (65) We sought to see whether the same can be documented for 
the PLEVA variant we describe herewith and also studied 20 classic cases of LyP for PVB19 
for comparison.  
 
Material and Methods 
Inclusion/exclusion criteria 
The inclusion criteria were:  
1) clinical appearances compatible with PLEVA supported by histopathological features 
typical for the disease,  
2) lack of waxing and an and waning of the lesions as typical for LyP, and  
3) presence in the infiltrate of a considerable number of small (or sometimes medium-sized) 
CD30+ lymphocytes as detected immunohistochemically. 
 
Excluded were cases in which there was at least a single large CD30+ cell, even if the clinical 
features were compatible with PLEVA as well as cases in which the histological features were 
suggestive for PLEVA but the clinical diagnosis of LyP could not be excluded with certainty. 
Thus, of 21 cases collected prospectively during 2003-2010, 8 were excluded following the 
clinicopathological correlation and follow-up studies.  
 
Light microscopic and immunohistochemical studies 
In all cases 1 to 18 hematoxylin and eosin stained sections were reviewed. 
Immunohistochemical studies were performed using the following antibodies: CD2 (1:50, 
Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), CD3 (1:75, Dako, Glostrup, 
Denmark), CD4 (1:2, Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), CD7 (1:25, 
Dako, Glostrup, Denmark), CD8 (1:400, Dako, Glostrup, Denmark), CD20 (1:600, Dako, 
Glostrup, Denmark), CD30 (1:75; Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), 
CD45RO (1:100; Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), CD45RA 
(1:100; Novocastra/Leica-Microsystems, Heerbrugg, Switzerland), CD56 (RTU, 
Novocastra/Leica-Microsystems, Heerbrugg, Switzerland, TIA (1:50, Immunotech Marseille, 
France), and EBER in situ hybridization (RTU, Novocastra/Leica-Microsystems, Heerbrugg, 
Switzerland)Appropriate positive controls were included. The number of antibodies used 
varied among individual cases depending on the available tissue.  
 
Molecular biologic studies 
To ensure uniform results, all cases were studied for TCR clonality and for PVB19 in a single 
laboratory (Dermatopathology, Friedrichshafen, Germany). The detailed description of the 
technique was described elsewhere. (44), (65) In brief, the TCR clonality studies were 
performed by using three multiplex PCRs with different primers from the variable region in 
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 5 
each reaction (reaction 1; Vg1–8, reaction 2; Vg9, and reaction 3: Vg10, Vg11, and Vg12) 
and the same Cy-5-labeled primers from the conserved region (JGP1/2, JG1/2, and JGP). This 
approach reliably permits elimination of pseudoclonality. A PCR analysis with the primers 
specific for VP1/VP2 regions of PVB19 genome was used to study the presence of the virus 
DNA in the lesional tissue. (65) 
 
Control group 
The 20 patients with LyP (10 women and 10 men, age range 12-64 years, mean 40.5) with 
available tissue blocks were randomly selected from our files. In all cases, clinicopathological 
correlation ensured the correct diagnosis. The cases were studied for TCR gene 
rearrangements and PVB19 as described above. 
 
Results 
Clinical data 
There were 10 female and 3 male PLEVA patients whose age at diagnosis ranged from 7 to 
89 years (mean 41 years; median 39 years). The clinical manifestation at the time of biopsy is 
indicated for each case in Table 1. In many cases, the features were of those PLEVA, with 
small erythematous macules quickly evolving into necrotic papules (Figures 1, 2). Although 
the clinical diagnostic consideration in some cases included LyP, there was no waxing and 
waning course on follow-up in any of the cases.  
 
Histopathologic and immunohistochemical findings 
In all cases, there were features of interface dermatitis with vacuolar alteration at the 
dermoepidermal junction accompanied by a lichenoid infiltrate, keratinocyte necrosis and 
erythrocyte extravasation. In addition to the lichenoid infiltrate at the junction, in many cases 
there were perivascular lymphocytes in the deep vascular plexus resulting in an overall 
wedge-like appearance of the infiltrate. The lymphocytes were small and well-differentiated 
but in 9 cases few medium sized monomorphic lymphoid cells were also recognized. Only 
occasional mild pleomorphic lymphocytes were noted, whereas neither large nor strikingly 
pleomorphic cells were present. Periadnexal distribution of cells has also been noted in some 
cases. Remarkably, in 8 cases signs of small vessel lymphocytic vasculitis with vascular wall 
destruction and fibrin deposits were recognized. This was a focal and discrete finding often 
seen only in step sections. Variably present features included mild acanthosis, focal 
epidermotropism of lymphocytes or neutrophils, spongiosis, and parakeratosis, and prominent 
edema in the papillary dermis (Figures 3A, 4A,B). 
 
Immunohistochemically, in 7 cases more than half (60-80%) of small and medium sized 
lymphocytes expressed CD30 (Figures 3B, 4C). In 4 cases, CD30 labeled around 40% of the 
cells and in the remaining 2 cases, there were only 15-20% of CD30 positive cells which 
nevertheless formed small but distinct clusters. Both intradermal and intraepidermal 
lymphocytes stained for CD30 but in rare biopsy specimens (even from the same patient) 
there was predominant staining of either component (Figure 5) Eight of the 13 PLEVA cases 
displayed a high number of CD8-positive cells and showed co-expression of CD8 and CD30 
in the intraepidermal and dermal component of the infiltrate (Figures 3C, 4D). The results of 
staining for the remaining markers are present in Table 1. 
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Molecular biological findings 
Of the 11 cases of PLEVA studied for TCR gene rearrangement, 6 evidenced a monoclonal T-
cell population and 5 were polyclonal. PVB19 was identified in 4 of the 10 cases investigated. 
 
In the control LyP group, 7 of the 20 cases manifested monoclonal TCR rearrangements, 10 
proved to be polyclonal, and in the remaining 3 cases the quality of the extracted genomic 
DNA permitted no reliable interpretation. No PVB19 was identified in 17 specimens, whereas 
inconclusive findings were seen with the remaining 3 specimens, also possibly to suboptimal 
DNA quality. 
  
Discussion  
Histopathologically, all included cases of PLEVA manifested typical features of the disease. 
An unusual aspect was the presence of CD30 positive cells which required the distinction 
from LyP. Traditionally, 3 histopathologic subtypes of LyP are recognized, including type A 
(histiocytic), type B (mycosis fungoides like), and type C (anaplastic large cell lymphoma—
like). (21) Recently, a fourth variant, the so-called LyP, type D has been proposed. (59) 
Saggini et al (59) reported 9 patients (mean age 29 years) who presented with typical clinical 
features of LyP (waxing and waning, self-resolving papules) but there were unusual 
histopathological findings, with prominent epidermotropism occasioning a resemblance to 
pagetoid reticulosis or primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell 
lymphoma. (3)  
 
Our cases further demonstrate a great overlap of PLEVA with some LyP forms but in none of 
the included cases were there typical clinical features of LyP with waxing and waning course 
evident on follow-up. Additionally, no large CD30 cells were present. However, if our 
exclusion criteria are also taken into account, the sharp histopathological demarcation of some 
cases of PLEVA and LyP appear very difficult and the diagnosis might require 
clinicopathological correlation or even follow-up. Despite common claims that the two 
diseases are easily distinguished one from another histopathologically, it becomes evident that 
with the recognition of new variants the relation between PLEVA and LyP might be closer as 
traditionally thought. (6), (4), (5), (13), (22) , (69), (70), (78), (79) Although LyP is 
considered a lymphoma at present, it has an overall survival rate of 100%, and basically the 
most important argument for classification of the disease as malignant is its rare association 
with overt and in some cases clonally related cutaneous or extracutaneous lymphomas. (27), 
(72), (80) Parenthetically, association or progression to mycosis fungoides or another 
lymphoma type has been documented in PLEVA. (14), (26), (33), (40), (45), (54), (60), (64), 
(66), (8) 
  
Remarkably, eight of our 13 PLEVA cases (62%) displayed a high number of CD8-positive 
cells and showed coexpression of CD8 and CD30 in the intraepidermal and dermal 
component of the infiltrate. Therefore and due to the presence of necrotic keratinocytes, some 
of our cases histologically simulated primary cutaneous aggressive epidermotropic CD8-
positive T-cell lymphoma (CD8+ AECTCL). The simultaneous expression of CD30 in our 
PLEVA cases, however, differed from CD8+ AECTCL, which is consistently negative ((3) 
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 7 
Emilio Berti, MD, Milan, Italy, personal communication). Finally, the clinical presentation 
clearly argued against CD8+ AECTCL.Apart from LyP, from a histopathological prospective, 
another differential diagnosis for the CD30+ PLEVA cases is the small cell variant of CD30+ 
large cell lymphoma which occurs in the skin extremely rarely and differs from the above 
PLEVA variant by the clinical manifestation with solitary nodules or tumors. (2), (38), (43). 
 
An interesting observation in our cohort of PLEVA with numerous CD30-positive cells is the 
frequent occurrence of small vessel vasculitis with fibrinoid necrosis of vesell walls and 
lymphocytic infiltration, although these findings were discrete. This appears to be in line with 
the observation of some authors who detected slight vascular deposits of IgM and C3 in most 
lesions they studied. (16), (49) True lymphocytic vasculitis can occasionally be seen in 
PLEVA. Leukocytoclastic vasculitis is rare but appears to be overrepresented in cases of the 
febrile ulceronecrotic variant. In contrast, vasculitis is a rare finding in LyP.  
 
Immune complex mediated vasculitis theory is one of the major theories of the etiology and 
pathogenesis of PLEVA. (16), (15), (24), (32), (51) The other 2 main hypotheses are (i) the 
theory of an inflammatory reaction triggered by infectious agents and (ii) PLEVA 
representing a lymphoproliferative disorder which has therefore been designated as T-cell 
dyscrasia by some authors. (11), (37) As far as the infectious theory is concerned, 
immunologic or hypersensitivity reaction against an infectious agent in particular, 
perturbation of the immunological homeostasis of keratinocytes with the subsequent 
activation of TCR-restricted effector cytotoxic T cells has been suggested as a pathogenetic 
mechanism. However, the causative agent of the disease remains unknown (for review see 
(11). Tomasini et al. studied PVB19 in PLEVA and detected the virus in 3 of 10 investigated 
cases. (65) We identified PVB19 in 4 of the 10 cases tested, and, interestingly, there were 2 
patients with known positive serology for the virus. In our control LyP group, in none of the 
specimens was PVB19 found.  
 
PVB19 is a member of the parvoviridae family, being the causative agent of early childhood 
fifth disease and papular-purpuric gloves and socks syndrome. (31), (50), (61) An association 
of PVB19 infection with connective tissue disease-like symptoms has recently been 
demonstrated. (47) Noteworthy, the authors of that paper showed a consistent constellation of 
histopathological features including vacuolar interface alteration, a lymphoid lichenoid and a 
perivascular infiltrate regardless of the clinical presentation of a particular case. (47) Other 
viruses have been episodically detected in the PLEVA but no firm association has so far been 
identified. (9), (10) The presence of PVB19 DNA in conjunction with a positive serology in 
two patients may suggest that PVB19 is pathogenetically linked to PLEVA at least in a subset 
of cases. The presence of CD30-positive lymphocytes and CD8-positive lymphocytes would 
be consistent with an inflammatory antiviral response, since CD30-positive, even atypically 
appearing lymphoid cells have been identified in viral skin diseases such as molluscum 
contagiosum and herpes virus infections. (39),  (76).  
 
Occurrence of clonal T-cells in PLEVA is the main argument to support the theory that the 
disease represents a lymphoproliferative process. However, the data on the presence of 
monoclonal T-cell populations in PLEVA are conflicting, with a wide variation between the 
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studies. (19), (42), (46), (62), (73), (74) Tomasini et al. suggested that this can be explained 
by variations in methodology and histopathological criteria used by different authors. (65) As 
far as the former aspect is concerned, so called T-cell pseudoclonality can apparently not be 
excluded in the previous reports. When this bias is eliminated technically, the monoclonality 
detection rate in PLEVA has been found to be about 10%. (65) . Using the same technique, 
we detected monoclonal T-cell population in 6 of the 11 cases (55%) studied, the detection 
rate being higher than in the control LyP group in which 7 of the 17 investigated cases (41%) 
proved monoclonal. This is in accordance with earlier studies which demonstrated that clonal T 
cells can only be detected in a minority of LyP cases and appear to be restricted mostly to LyP 
type C. (30) In the most common LyP, type A, the investigators found no clonal T cells 
among 9 cases studied. (30) Of the 5 cases of LyP type D studied for TCR gene 
rearrangements, 2 were monoclonal and 3 polyclonal. (59) Altogether, these findings indicate 
that the results of clonality studies cannot be a differential diagnostic criterion.  
 
In conclusion, we have described what we believe to represent an unusual variant of PLEVA 
characterized by the typical clinical features/course but an unusual conspicuous CD30+ 
infiltrate of small to medium sized lymphocytes. Additionally, about half of the cases 
demonstrated a T-cell clonal population and presence of PVB19 DNA. Although the virus 
was typically absent in the control group of LyP, the detection rate does not allow to draw a 
conclusion that PVB19 is a causative agent for PLEVA. The main differential diagnosis 
condition of this unusual PLEVA variant is LyP, and from a histological point of view also 
the papular form of mycosis fungoides as well as primary cutaneous aggressive 
epidermotropic T-cell lymphoma. Admittedly, the CD30+ PLEVA described herein and LyP 
show a great overlap if one takes into account all known variations. This suggests that LyP 
and PLEVA may be much more biologically closely related entities than currently thought or 
even can occur on a clinicopathological spectrum. 
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Figure legends 
 
Figure 1. Multiple small macules that rapidly evolve into crusted papules (Case 8) 
 
Figure 2. Close-up of necrotic papules with crusts and peripheral collaret (Case 1) 
 
Figure 3. Typical features of pityriasis lichenoides et varioliformis acuta, including 
parakeratosis, acanthosis, vacuolar alteration at the dermoepidermal junction, spongiosis, 
occasional necrotic keratinocytes  and epidermotropism of small lymphocytes can be 
recognized (A). Staining for  CD30 (B) and CD8 (C). (Case 2) 
 
Figure 4. In this case more severe vacuolar alteration, keratinocyte necrosis and erythrocyte 
extravasation are evident. Note also occasional medium sized lymphocytes within the 
epidermis (A, B). Staining for CD30 (C) and CD8 (D) (Case 8) 
 
Figure 5. Predominant staining for CD30 of the intraepidermal component. This is the same 
patient (Case 2) as depicted in Figure 3. 
  
Figure 6. Monoclonal TCR rearrangement  (Case 2) evident as a peak in the upper line. The 
middle line represent a reference line and the lower line is a negative control.  
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Table 1. Main clinicopathological, immunohistochemical and molecular biological data 
 
Case Age/Se
x 
Clinical features/impression Infiltrate  Lymphocytes Other dermal 
changes  
Epidermal  
changes 
ICH TCR PV B19 
Case 1 M/65 Crusted papules, purpura. 
Necrotic vasculitis? 
Li, Ep,  
PV, PA 
Small, few 
medium sized 
EE, Vas A, P, VA, NK, 
Sp, Neu 
CD2 90%; CD3 70%; CD4 50%; CD7 40%; CD8 80%; 
TIA1 50%;CD30 15%;CD20 5%;CD45RO-; CD45RA-; 
CD56-;CD123-;EBER- 
+ - 
Case 2 M/44 Generalized partly necrotic 
papules. PLEVA? LyP? 
Li, Ep, 
PV, PA 
Small, few 
medium sized 
EE A, P, VA, NK, 
Sp, Neu  
CD2 90%;CD3 20%; CD4 20%; CD7 80%; CD8 60%; 
CD30 40%; CD45RA 5%; CD45RO 90%; CD56-; EBER- 
+ - 
Case 3 F/31 Multiple lesions on the upper 
limbs. Lymphoma? 
Li, PV Small, few 
medium sized 
EE, PDE 
 
A, P, VA, NK 
Subepiderm 
edema 
CD4 20%; CD8 90%; CD30 80% + + 
Case 4  F/39 Generalized eruption. PLEVA? 
LyP? Varicella?  
Li, PV, 
PA syring 
Small, few 
medium sized 
EE, Vas VA, NK  CD4 70%; CD8 90%; TIA1 70%; CD30 70% + + 
(serology
+) 
Case 5 F/51 Three month history of partly 
necrotic pruritic papules and 
macules. 
Lz, PV Small EE P, VA, NK  CD2 90%; CD4 90%; CD7 30%; CD8 60%; TIA1 
50%;CD30 80%; CD45RO 50%-; CD45RA10; CD56-; 
EBER- 
- - 
Case 6 F/13 Generalized papular macular 
eruption. PLEVA? LyP? PG? 
Lues? 
Li, PV, 
PA 
Small EE A, P, VA, Sp, 
Nk, Neu 
CD2 70%; CD3 20%; CD7 70%; CD8 60%; TIA1 
60%;CD30 40%; CD45RO 30%; CD45RA 20%; CD56-;; 
EBER- 
+ + 
Case 7 M/60 Two month history of 
symmetric varioliform papules.  
Li, Ep, 
PV, PA 
Small, few 
medium sized 
EE, PDE, Vas P, VA, Sp, 
Nk,  
CD2 60%; CD3 70 %; CD4 80%; CD8 70 %; TIA1 
5%;CD30 60%;CD20 5%; ;EBER- 
- + 
Case 8 F/28 PLEVA? Li, Ep, 
PV, PA 
Small, medium 
sized 
EE, PDE, Vas A, P, VA, NK, 
Sp, Neu 
CD2 30 %; CD3 30%; CD4 30%; CD7  40%; CD8 80%; 
TIA1 10%;CD30 80%;CD20 5%; CD56 -;; EBER- 
- - 
(serology
+) 
Case 9 F/7 Three month history of 
generalized popular lesions 
Li, Ep, 
PV,  
Small EE, Vas A, P, VA, NK, 
Sp,  
CD3 %; CD4 20%; CD7  30%; CD8 50%; CD30 40%; 
EBER- 
ND ND 
Case 10 F/14 Multiple papules Li, Ep, 
PV,  
Small EE, Vas A, P, VA, NK, 
Sp, Neu 
CD8 70%; TIA1 40%;CD30 40%;  ND ND 
Case 11 F/89 Generalized hemorrhagic 
papular lesions. Vasculitis? 
Li, Ep, PV Small, few 
medium sized 
EE, PDE, Vas P, NK, VA, 
Sp, Neu 
CD4 50%; CD8 90%; CD30 60%;; TIA 60% - - 
Case 12 F/38 Prurigo somplex acuta? Li, PV, 
PA, Ep 
Small, few 
medium sized 
EE, Vas A, P, NK, VA, 
Sp Neu 
CD2 90%; CD3 90%; CD4 40%; CD8 60%; CD30 70 %; 
CD45RA 10%; CD45R0 100%;; TIA 80%;   
+ - 
Case 13 F/59 9 month history of 
hyperkeratotic papules and 
macules on the limbs and trunk. 
PLEVA? 
Li, PV,  
Ep 
Small, few 
medium sized 
EE A, P, NK, VA, 
SP, Neu 
CD2 90%; CD4 90%; CD7 60%; CD8 60%; CD30 20 %; 
TIA 10%;   
- ND 
 
 
PLEVA pityriasis lichenoides et varioliformis acuta 
LyP lymphomatoid papulosis 
PG psoriasis gutatte 
Li lichenoid 
PV perivascular 
PA periadenxal 
Tables
Ep focal epidermotropism 
EE erythrocyte extarvasation 
Vas vasculitis 
PDE papillary dermis edema 
A acanthosis 
P parakeratosis 
VA vacuolar alteration 
NK necrotic keratinocytes 
Sp spongiosis  
Neu Neutrophils 
TCR T- cell receptor rearrangement studies  
PVB 19 Parvovirus B19 
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